Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
NCT: NCT05804318 · RECRUITING
広告
NCT識別子NCT05804318
ステータスRECRUITING
開始日2023-04-13
SponsorVarian, a Siemens Healthineers Company (INDUSTRY)
First posted
Last updated
概要
This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the patient reported EPIC-26 questionnaire, compared with the historically reported rate for non-adaptive, non-urethral sparing prostate SBRT.
公式ソース
ClinicalTrials.govで見る →データはClinicalTrials.gov APIから取得しています。最新のステータスは公式記録をご確認ください。